Again Acquires Genomatica: Combining AI-Driven Discovery with Industrial Biomanufacturing
Again (Denmark) acquired Genomatica (Geno) on August 12, 2026 to merge its CO₂ to chemical scale up with Geno's AI driven molecule discovery platform. The combined company estimates its capacity to divert up to 85 million tons of CO₂ per year through direct capture and avoided emissions.
Published byEdited with DeepSeek-V4-FlashImages generated with GPT Image 1.5
Again (Denmark) acquired Genomatica (Geno) on August 12, 2026 to merge its CO₂ to chemical scale up with Geno's AI driven molecule discovery platform.
The combined company estimates its capacity to divert up to 85 million tons of CO₂ per year through direct capture and avoided emissions.
What key details are available about Again's acquisition of Genomatica (Geno), including the strategic rationale, capabilities combined, finAI-generated editorial visualization of the combined Again and Genomatica biomanufacturing platform.
AI Prompt
Create a landscape editorial hero image for this Studio Global article: What key details are available about Again's acquisition of Genomatica (Geno), including the strategic rationale, capabilities combined, fin. Article summary: Now let me get the additional detail on the CEO statement and commercial models from the official sourcesHere is a comprehensive breakdown of the acquisition based on the official announcement and trusted industry report. Topic tags: general, general web, user generated. Style: premium digital editorial illustration, source-backed research mood, clean composition, high detail, modern web publication hero. Use reference image context only for broad subject, composition, and topical grounding; do not copy the exact image. Avoid: logos, brand marks, copyrighted characters, real person likenesses, fake screenshots, UI text, readable text, watermarks, charts with fa
openai.com
On August 12, 2026, Denmark-based Again (LuaBio ApS) announced the acquisition of Genomatica Inc., widely known as Geno, the San Diego-based pioneer in industrial bioprocess engineering . The deal fuses Again's biomanufacturing scale-up capabilities with Geno's AI-driven discovery and design platform for biomolecules, creating an end-to-end engine from molecule design to commercial production . Financial terms were not disclosed .
Studio Global AI
Continue your research
This page includes a source-backed answer you can continue inside Studio Global.
What is the short answer to "Again Acquires Genomatica: Combining AI-Driven Discovery with Industrial Biomanufacturing"?
Again (Denmark) acquired Genomatica (Geno) on August 12, 2026 to merge its CO₂ to chemical scale up with Geno's AI driven molecule discovery platform.
What are the key points to validate first?
Again (Denmark) acquired Genomatica (Geno) on August 12, 2026 to merge its CO₂ to chemical scale up with Geno's AI driven molecule discovery platform. The combined company estimates its capacity to divert up to 85 million tons of CO₂ per year through direct capture and avoided emissions.
Again Acquires Genomatica: Combining AI-Driven Discovery with Industrial Biomanufacturing
Again (Denmark) acquired Genomatica (Geno) on August 12, 2026 to merge its CO₂ to chemical scale up with Geno's AI driven molecule discovery platform. The combined company estimates its capacity to divert up to 85 million tons of CO₂ per year through direct capture and avoided emissions.
Published byEdited with DeepSeek-V4-FlashImages generated with GPT Image 1.5
Again (Denmark) acquired Genomatica (Geno) on August 12, 2026 to merge its CO₂ to chemical scale up with Geno's AI driven molecule discovery platform.
The combined company estimates its capacity to divert up to 85 million tons of CO₂ per year through direct capture and avoided emissions.
What key details are available about Again's acquisition of Genomatica (Geno), including the strategic rationale, capabilities combined, finAI-generated editorial visualization of the combined Again and Genomatica biomanufacturing platform.
AI Prompt
Create a landscape editorial hero image for this Studio Global article: What key details are available about Again's acquisition of Genomatica (Geno), including the strategic rationale, capabilities combined, fin. Article summary: Now let me get the additional detail on the CEO statement and commercial models from the official sourcesHere is a comprehensive breakdown of the acquisition based on the official announcement and trusted industry report. Topic tags: general, general web, user generated. Style: premium digital editorial illustration, source-backed research mood, clean composition, high detail, modern web publication hero. Use reference image context only for broad subject, composition, and topical grounding; do not copy the exact image. Avoid: logos, brand marks, copyrighted characters, real person likenesses, fake screenshots, UI text, readable text, watermarks, charts with fa
openai.com
On August 12, 2026, Denmark-based Again (LuaBio ApS) announced the acquisition of Genomatica Inc., widely known as Geno, the San Diego-based pioneer in industrial bioprocess engineering . The deal fuses Again's biomanufacturing scale-up capabilities with Geno's AI-driven discovery and design platform for biomolecules, creating an end-to-end engine from molecule design to commercial production . Financial terms were not disclosed .
Studio Global AI
Continue your research
This page includes a source-backed answer you can continue inside Studio Global.
What is the short answer to "Again Acquires Genomatica: Combining AI-Driven Discovery with Industrial Biomanufacturing"?
Again (Denmark) acquired Genomatica (Geno) on August 12, 2026 to merge its CO₂ to chemical scale up with Geno's AI driven molecule discovery platform.
What are the key points to validate first?
Again (Denmark) acquired Genomatica (Geno) on August 12, 2026 to merge its CO₂ to chemical scale up with Geno's AI driven molecule discovery platform. The combined company estimates its capacity to divert up to 85 million tons of CO₂ per year through direct capture and avoided emissions.
Data is the core asset. Again told multiple outlets that the deal is fundamentally about acquiring Geno's AI computational biotech platform and patent portfolio, which includes decades of experimental results, structural data, scale-up insights, and development outcomes . More data sharpens Again's computational models and compresses the timeline from molecule discovery to market .
End-to-end capability. The two companies previously operated on different sides of biomanufacturing. Again focused on CO₂-to-chemical fermentation at scale via modular bioreactors co-located with industrial emitters, using engineered Moorella bacteria. Geno specialized in sugar-based fermentation using engineered E. coli and AI-guided pathway design. The merger creates what the companies describe as an "AI design-to-scale" engine .
Geopolitical timing. The acquisition arrives amid reshoring tailwinds from the U.S. BIOSECURE Act and the EU's Biotech Act II, policies expected to mobilize tens of billions of dollars in domestic bio-based supply chains .
Existing ties. Geno co-founder Christophe Schilling already sat on Again's board of directors, indicating a pre-existing strategic relationship .
Capabilities Combined
Again
Genomatica (Geno)
Modular bioreactors co-located with industrial CO₂ emitters
AI and computational platform for de novo molecule discovery and design
Engineered Moorella bacteria converting CO₂ + H₂ into acetate, acetic acid, and derivatives
Engineered E. coli strains fermenting plant sugars into chemicals
AI-driven bioprocess design suite and scale-up modeling
20+ years of in silico pathway/strain design and ML analytics
Commercial-scale acetic acid plant in Texas (since 2025)
Licensed commercial processes for BDO, nylon precursors, palm oil alternatives
Operations in Copenhagen, Munich, and Houston
Partnerships with Novamont, Qore (Cargill/Helm), Unilever, Kao, Aquafil
Combined emissions impact: The companies estimate that the combined platform can divert up to 85 million tons of CO₂ per year through direct capture and avoided emissions . This figure mixes direct capture with avoided emissions and is based on the companies' own estimates.
The acquisition also gives Again access to Geno's intellectual property, computational models, and decades of process development data . Again says the purchase will help it expand into other renewable feedstocks, including sugars .
Financial Terms: Undisclosed
Neither company revealed the purchase price or deal structure . For context, Again had raised $67 million since its 2021 founding, per PitchBook .
Future Commercial Model: License, Co-Develop, and Sell
The combined company will operate a diversified, three-pronged commercial approach :
Licensing technology where it scales, continuing Geno's model of licensing processes to manufacturers like Novamont and Qore.
Co-developing production pathways where they are mission-critical for partners.
Selling products from existing and upcoming assets, including Again's own production facilities.
This model is designed to "capture value at every stage" of the biomanufacturing value chain .
CEO Statement
Max Kufner, CEO of Again, said:
"AI is revolutionizing biology, but algorithms are only as good as their ability to translate into real-world, commercial-scale execution. Geno pioneered AI and computational biotechnology for molecule discovery and design. By integrating that with our scale-up platform and novel feedstock technologies, we are building the world's leading biomanufacturing platform, unlocking novel products and supply-chains that industries critically need."
Key Caveats
Financial terms remain undisclosed .
The emissions figure of 85 million tons CO₂/year is based on the companies' own estimates and mixes direct capture with "avoided emissions" .
All existing Geno partners "will continue to be supported throughout the transition" .
siliconangle.com
Again acquires Geno to advance biomanufacturing at scale with AI ...
Data is the core asset. Again told multiple outlets that the deal is fundamentally about acquiring Geno's AI computational biotech platform and patent portfolio, which includes decades of experimental results, structural data, scale-up insights, and development outcomes . More data sharpens Again's computational models and compresses the timeline from molecule discovery to market .
End-to-end capability. The two companies previously operated on different sides of biomanufacturing. Again focused on CO₂-to-chemical fermentation at scale via modular bioreactors co-located with industrial emitters, using engineered Moorella bacteria. Geno specialized in sugar-based fermentation using engineered E. coli and AI-guided pathway design. The merger creates what the companies describe as an "AI design-to-scale" engine .
Geopolitical timing. The acquisition arrives amid reshoring tailwinds from the U.S. BIOSECURE Act and the EU's Biotech Act II, policies expected to mobilize tens of billions of dollars in domestic bio-based supply chains .
Existing ties. Geno co-founder Christophe Schilling already sat on Again's board of directors, indicating a pre-existing strategic relationship .
Capabilities Combined
Again
Genomatica (Geno)
Modular bioreactors co-located with industrial CO₂ emitters
AI and computational platform for de novo molecule discovery and design
Engineered Moorella bacteria converting CO₂ + H₂ into acetate, acetic acid, and derivatives
Engineered E. coli strains fermenting plant sugars into chemicals
AI-driven bioprocess design suite and scale-up modeling
20+ years of in silico pathway/strain design and ML analytics
Commercial-scale acetic acid plant in Texas (since 2025)
Licensed commercial processes for BDO, nylon precursors, palm oil alternatives
Operations in Copenhagen, Munich, and Houston
Partnerships with Novamont, Qore (Cargill/Helm), Unilever, Kao, Aquafil
Combined emissions impact: The companies estimate that the combined platform can divert up to 85 million tons of CO₂ per year through direct capture and avoided emissions . This figure mixes direct capture with avoided emissions and is based on the companies' own estimates.
The acquisition also gives Again access to Geno's intellectual property, computational models, and decades of process development data . Again says the purchase will help it expand into other renewable feedstocks, including sugars .
Financial Terms: Undisclosed
Neither company revealed the purchase price or deal structure . For context, Again had raised $67 million since its 2021 founding, per PitchBook .
Future Commercial Model: License, Co-Develop, and Sell
The combined company will operate a diversified, three-pronged commercial approach :
Licensing technology where it scales, continuing Geno's model of licensing processes to manufacturers like Novamont and Qore.
Co-developing production pathways where they are mission-critical for partners.
Selling products from existing and upcoming assets, including Again's own production facilities.
This model is designed to "capture value at every stage" of the biomanufacturing value chain .
CEO Statement
Max Kufner, CEO of Again, said:
"AI is revolutionizing biology, but algorithms are only as good as their ability to translate into real-world, commercial-scale execution. Geno pioneered AI and computational biotechnology for molecule discovery and design. By integrating that with our scale-up platform and novel feedstock technologies, we are building the world's leading biomanufacturing platform, unlocking novel products and supply-chains that industries critically need."
Key Caveats
Financial terms remain undisclosed .
The emissions figure of 85 million tons CO₂/year is based on the companies' own estimates and mixes direct capture with "avoided emissions" .
All existing Geno partners "will continue to be supported throughout the transition" .
siliconangle.com
Again acquires Geno to advance biomanufacturing at scale with AI ...
